| Old Articles: <Older 6991-7000 Newer> |
|---|
 |
Pharmaceutical Executive
December 1, 2010
Jill Wechsler |
New Ballgame in Washington Republican gains in Congress create uncertainty for health reform, drug regulation, and biomedical research   |
Pharmaceutical Executive
December 1, 2010
Chaturvedi & French |
US Anti-Corruption Regulation Risks Stepped-up enforcement of the Foreign Corrupt Practices Act requires enhanced global coordination of compliance |
Pharmaceutical Executive
December 1, 2010
David Chapin |
Taking Advantage of the Science Behind Marketing Being strategic and applying data tools effectively will go a long way in helping to produce analytics that drive sales |
Pharmaceutical Executive
December 1, 2010
Andrea LaFountain |
Adherence Equation: The Code is Cracked! Putting science front-and-center in the design of patient adherence programs can lead to a better understanding of the commitment required to get patients to take their medicine |
Pharmaceutical Executive
December 1, 2010
William Looney |
Emerging Stakeholders with Clout: The Press Power Behind ProPublica ProPublica is a new, independent, non-profit newsroom that produces investigative journalism in the public interest. With ProPublica turning its attention to the healthcare industry, how should the industry respond? |
Pharmaceutical Executive
December 1, 2010
William Looney |
Is Euroland Following the US Disclosure Lead? Cegedim Relationship Management survey documents whether European industry is ready for the challenge of new compliance and disclosure risks on promotional spending. |
Pharmaceutical Executive
December 1, 2010
Sandra Stahl |
Gentle Collisions in Marketing Healthcare marketing in today's post-recession economy is not about one-size-fits-all vehicles, but rather about bringing your product into consumers' lives in a series of personal, non-invasive ways |
Pharmaceutical Executive
December 1, 2010
Ansis Helmanis |
A New Twist in the Cost Curve The strict regulatory divide between market authorization and price reimbursement is crumbling in the US. Is industry prepared to adapt or challenge? |
Pharmaceutical Executive
December 1, 2010
William Looney |
In Through the Out Door The end of anther year is an appropriate time to highlight the march of time and the transitions that accompany it in Europe and in China. |
Pharmaceutical Executive
December 1, 2010 |
PharmEssentia: The 30-Year Dream "In my mind," says Ko-Chung Lin, founder, president, and CEO of Taiwan's PharmaEssentia, "the story of AstraZeneca was particularly striking: it shows you can start a very small company and grow it to play a major role. |
| <Older 6991-7000 Newer> Return to current articles. |
